1994 Volume 42 Issue Supplement4 Pages 295-300
The antibacterial activity of biapenem (BIPM), a new carbapenem, was evaluated: its MIC90 was≤0.0125μg/ml against Streptococcus pneumoniae (83 strains), ≤0.05μg/ml against Moraxella (Branhamella) catarrhalis (52 strains) and 3.13μg/ml against Haemophilus influenzae (52 strains), which were isolated from patients with respiratory tract infections.
BIPM was administered to 10 patients with respiratory tract infection and the clinical response was studied.
The patients consisted of 3 with chronic bronchitis, 2 with chronic pulmonary emphysema, 2 with bronchial asthma and 3 with pneumonia. 0.3-0.6g of the drug was dissolved in 100ml of saline, and patients were treated with BIPM 0.6-1.2g daily via i.v. drip infusion. The duration of treated ranged from 8-15 days.
Clinical efficacy was good in 7, fair in 2 and poor in 1. The efficacy rate was 70%.
Ten of the 11 causative organisms (4/5 Pseudomonas aeruginosa, 3/3 Streptococcus pneumoniae, 2/2 Haemophilus influenzae, 1/1 Moraxella (Branhamella) catarrhalis) were eradicated. No side effects were observed. But slight elevation of transaminase was observed in 2 cases.
